NCT03468985 2023-10-17Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Completed3 enrolled 10 charts